Medical Director

The Medical Director, Early Assets will report to the VP, Early Assets and will be responsible for developing, leading, and executing the medical strategy and scientific engagement for multiple early-stage CNS clinical programs, including assets being developed for Cerebral Amyloid Angiopathy (CAA), Alzheimer’s disease, and Huntington’s disease. The successful candidate will serve as the primary point of contact for Clinical Development and Value & Pipeline Commercialization teams and be the medical affairs delegate on the Program Team to ensure that the Medical Affairs perspective and the voice of the patient and health care provider are incorporated into early development and commercialization strategies. This is a critical role in driving medical strategy and execution excellence, enabling commercial growth objectives through evidence generation, thought leadership, scientific engagement and product expertise.

Provide strategic and scientific leadership to and define global Medical Affairs strategy for CNS early-stage clinical programs. Serve as a key member of the product development teams and meaningfully impact clinical development plans, study design, and data interpretation. Lead and execute global scientific engagement strategy and drive excellence in scientific engagement with all key stakeholders. Develop, initiate, and maintain strong relationships with international scientific leaders and key stakeholders to enhance awareness of Alnylam’s early asset portfolio. Organize and manage global expert events (advisory boards, expert panels, symposia). Functions as the scientific medical expert internally and externally with national and international stakeholders. Serve as a collaborator and key stakeholder in global clinical operations, global commercial development, global market access, global clinical R&D, global pharmacovigilance, and the promotion review committee (PRC) on medical aspects of the company’s products. Provide strategic medical insights into R&D and commercialization strategies including profiling patient pathways, mapping the treatment landscape, and understanding prescriber patterns and dynamics. Serve as the Medical Affairs lead for strategic partnerships: Partner with Value & Evidence Strategy team to develop and execute against integrated evidence generation plans Partner with the Medical Communications team to ensure the development of global communication, strategy, and execution of timely and high-quality communication of scientific data (publication and medical congress) Partner with Medical Training team to develop and deliver high quality scientific and skill-based training to medical team across regions Partner with Omnichannel team to develop a strong Omnichannel prelaunch strategy for successful commercial launch. Liaise with global and regional Medical Affairs to ensure medical insights from all key markets are integrated into and inform product development. Oversee development and execution of comprehensive integrated evidence plans (IEP)s ensuring high-quality publications from all types of evidence throughout development, launch, and in-market for all Alnylam pipeline and inline products. Provide medical expertise and input into TA strategies ensuring close collaboration with R&D to deliver data and a label to support the Target Product Profile (TPP)s and reflect the value required to enable speedy patient access.

MD, PhD, Pharm D or equivalent ex-US medical degree 5+ years of demonstrated high-level professional knowledge and skills in Medical Affairs and R&D, especially familiarity with early clinical development, in the pharmaceutical or biotech industry. Deep therapeutic area knowledge and experience in Neurological Diseases. Extensive knowledge of the latest regulatory, policy, and technology developments preferred. Experience in global scientific engagement strategy including scientific congresses, external experts and panels,